These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 34910373)
1. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant. Serrano-Conde E; Leyva A; Fuentes A; de Salazar A; Chueca N; Pérez-Castro S; Regueiro B; Rojas A; Mendoza J; Rojas J; García F Transbound Emerg Dis; 2022 Sep; 69(5):2649-2655. PubMed ID: 34910373 [TBL] [Abstract][Full Text] [Related]
2. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S Front Immunol; 2021; 12():793191. PubMed ID: 34975897 [TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378 [TBL] [Abstract][Full Text] [Related]
4. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y Microbiol Spectr; 2021 Dec; 9(3):e0056121. PubMed ID: 34851162 [TBL] [Abstract][Full Text] [Related]
5. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD; Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254 [TBL] [Abstract][Full Text] [Related]
6. Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. Lafon E; Jäger M; Bauer A; Reindl M; Bellmann-Weiler R; Wilflingseder D; Lass-Flörl C; Posch W J Allergy Clin Immunol; 2022 Apr; 149(4):1242-1252.e12. PubMed ID: 35093484 [TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Newman J; Thakur N; Peacock TP; Bialy D; Elrefaey AME; Bogaardt C; Horton DL; Ho S; Kankeyan T; Carr C; Hoschler K; Barclay WS; Amirthalingam G; Brown KE; Charleston B; Bailey D Nat Microbiol; 2022 Aug; 7(8):1180-1188. PubMed ID: 35836002 [TBL] [Abstract][Full Text] [Related]
8. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252 [TBL] [Abstract][Full Text] [Related]
9. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. Noori M; Nejadghaderi SA; Arshi S; Carson-Chahhoud K; Ansarin K; Kolahi AA; Safiri S Rev Med Virol; 2022 Mar; 32(2):e2277. PubMed ID: 34286893 [TBL] [Abstract][Full Text] [Related]
10. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P Front Immunol; 2022; 13():816389. PubMed ID: 35464418 [TBL] [Abstract][Full Text] [Related]
11. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination. Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410 [TBL] [Abstract][Full Text] [Related]
12. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938 [TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Evans JP; Zeng C; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL Sci Transl Med; 2022 Mar; 14(637):eabn8057. PubMed ID: 35166573 [TBL] [Abstract][Full Text] [Related]
14. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity. Kara Z; Akçin R; Demir AN; Dinç HÖ; Taşkın HE; Kocazeybek B; Yumuk VD Obes Surg; 2022 Sep; 32(9):2987-2993. PubMed ID: 35802279 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination. Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K Front Immunol; 2022; 13():888794. PubMed ID: 35711424 [TBL] [Abstract][Full Text] [Related]
16. Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. Xia H; Zou J; Kurhade C; Cai H; Yang Q; Cutler M; Cooper D; Muik A; Jansen KU; Xie X; Swanson KA; Shi PY Cell Host Microbe; 2022 Apr; 30(4):485-488.e3. PubMed ID: 35245438 [TBL] [Abstract][Full Text] [Related]
17. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection. Tyner HL; Burgess JL; Grant L; Gaglani M; Kuntz JL; Naleway AL; Thornburg NJ; Caban-Martinez AJ; Yoon SK; Herring MK; Beitel SC; Blanton L; Nikolich-Zugich J; Thiese MS; Pleasants JF; Fowlkes AL; Lutrick K; Dunnigan K; Yoo YM; Rose S; Groom H; Meece J; Wesley MG; Schaefer-Solle N; Louzado-Feliciano P; Edwards LJ; Olsho LEW; Thompson MG Clin Infect Dis; 2022 Aug; 75(1):e827-e837. PubMed ID: 34928334 [TBL] [Abstract][Full Text] [Related]
18. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections. Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K Front Immunol; 2022; 13():946318. PubMed ID: 35928813 [TBL] [Abstract][Full Text] [Related]
19. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study. Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069 [TBL] [Abstract][Full Text] [Related]
20. The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients. Tolan NV; Sherman AC; Zhou G; Nabel KG; Desjardins M; Melanson S; Kanjilal S; Moheed S; Kupelian J; Kaufman RM; Ryan ET; LaRocque RC; Branda JA; Dighe AS; Abraham J; Baden LR; Charles RC; Turbett SE Microbiol Spectr; 2022 Apr; 10(2):e0021122. PubMed ID: 35311584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]